{"id":1696,"date":"2023-06-25T17:31:27","date_gmt":"2023-06-25T17:31:27","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/candesartan-cilexetil\/"},"modified":"2023-06-25T19:45:49","modified_gmt":"2023-06-25T19:45:49","slug":"candesartan-cilexetil","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/candesartan-cilexetil\/","title":{"rendered":"Candesartan cilexetil"},"content":{"rendered":"

<\/p>\n

Candesartan cilexetil<\/h1>\n

CLINICAL USE<\/h3>\n

Angiotensin-II antagonist:<\/p>\n

  • Hypertension<\/li>\n
  • Heart failure
    \n

    DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

    2\u201332 mg daily<\/p>\n

    PHARMACOKINETICS<\/h3>\n<\/li>\n
  • Molecular weight                           :610.7<\/li>\n
  • %Protein binding                           :>99<\/li>\n
  • %Excreted unchanged in urine     : 26<\/li>\n
  • Volume of distribution (L\/kg)       :0.1<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :9\/18
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Initial dose 2 mg and increase according to response<\/li>\n
  • <10           : Initial dose 2 mg and increase according to response
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Unlikely to be dialysed. Dose as for GFR <10 mL\/min<\/li>\n
  • HD                     :Not dialysed. Dose as for GFR <10 mL\/min<\/li>\n
  • HDF\/high flux   :Not dialysed. Dose as for GFR <10 mL\/min<\/li>\n
  • CAV\/VVHD      :Unlikely to be dialysed. Dose as for GFR 10 to 20 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Anaesthetics: enhanced hypotensive effect Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs<\/li>\n
  • Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity<\/li>\n
  • Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics<\/li>\n
  • Epoetin: increased risk of hyperkalaemia; antagonism of hypotensive effect<\/li>\n
  • Lithium: reduced excretion, possibility of enhanced lithium toxicityP<\/li>\n
  • otassium salts: increased risk of hyperkalaemia.<\/li>\n
  • Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • In patients with mild\u2013moderate renal impairment Cmax and AUC are increased by 50% and 70% respectively. Corresponding changes in patients with severe renal impairment are 50% and 110% respectively<\/li>\n
  • Adverse reactions, especially hyperkalaemia, are more common in patients with renal impairment<\/li>\n
  • Renal failure has been reported in association with angiotensin-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with congestive heart failure<\/li>\n
  • Close monitoring of renal function during therapy is necessary in those with renal insufficiency<\/li>\n","protected":false},"excerpt":{"rendered":"

    Candesartan cilexetil CLINICAL USE Angiotensin-II antagonist: Hypertension Heart failure DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1696","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1696"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1696\/revisions"}],"predecessor-version":[{"id":2859,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1696\/revisions\/2859"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}